Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma

Between October 1988 and November 1994, 100 patients with cutaneous metastases from malignant melanoma were treated by carbon dioxide laser ablation under local or general anaesthesia as appropriate. There were minimal postoperative complications and most wounds healed within 6 weeks. A total of 34 of the 53 patients in this series with stage IIIa disease were controlled with four or fewer laser ablations during the first year from presentation. This technique provides a simple effective alternative to hyperthermic isolated limb perfusion with melphalan. Patients with disease not controlled by laser can be considered for isolated limb perfusion.

[1]  K. Wakamatsu,et al.  The α‐MSH analogue Nle4DPhe7α‐MSH regulates melanin type in cultured human melanocytes , 1994 .

[2]  A. Paccagnella,et al.  Tamoxifen (JAM) and interferon alfa 2a (IFN) in metastatic melanoma , 1994 .

[3]  P. Pantazis,et al.  Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts , 1994, Melanoma research.

[4]  J. Thomas,et al.  Low‐dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusion , 1993 .

[5]  J. Thomas,et al.  Treatment of cutaneous metastases from malignant melanoma using the carbon-dioxide laser. , 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Thomas,et al.  Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb , 1990, The British journal of surgery.

[8]  D. Liénard,et al.  Results of 206 isolated limb perfusions for malignant melanoma. , 1989, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  S. Carlini,et al.  Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion , 1989, Cancer.

[10]  J. Fortner,et al.  Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard). , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Cumberlin,et al.  Isolation perfusion for malignant melanoma of the extremity: a review. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Müller,et al.  A Prospective Randomized Study of Regional Extremity Perfusion in Patients with Malignant Melanoma , 1984, Annals of surgery.

[13]  H. Schraffordt koops,et al.  Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs. , 1981, European journal of cancer.

[14]  C. Jamieson,et al.  Isolated limb perfusion with melphalan in the treatment of malignant melanoma , 1980, The British journal of surgery.

[15]  R. F. Ryan,et al.  Chemotherapy of Melanoma of the Extremities by Perfusion: Fourteen Years Clinical Experience , 1972, Annals of surgery.

[16]  R. F. Ryan,et al.  Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.